All In Biotech

NDA 021528 · Abbvie

Acular Ls

Ketorolac Tromethamine · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Mar 5, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

May 30, 2003

Approved uses

1

Original approval plus efficacy supplements

Registered trials

238

46 Phase 3, 16 recruiting

FAERS reports

4,453

2,549 serious, 258 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 21, 2024.

Ketorolac tromethamine ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery. Ketorolac tromethamine ophthalmic solution is a nonsteroidal, anti-inflammatory drug (NSAID) indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery. ( 1 )

Mechanism: Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ACULAR LS · KETOROLAC TROMETHAMINE 0.4% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Ketorolac Tromethamine" as an intervention, any sponsor and status, largest first.

All 238 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective491
  • drug hypersensitivity300
  • nausea255
  • headache248
  • pain241
  • dyspnoea227
  • fatigue219
  • treatment failure207
  • off label use163
  • vomiting161
  • diarrhoea150
  • product dose omission issue146

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200443
200571
200670
200769
200891
2009106
2010109
2011162
2012195
201369
201483
2015103
2016314
2017224
2018200
2019276
2020461
2021222
2022299
2023363
2024339
2025337
2026247

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Acular Ls (Ketorolac Tromethamine)

2024 spending

$21K

Beneficiaries

41

74 claims

Per beneficiary

$516

$45.98 per unit

View as table
YearSpending
2020$36,788
2021$22,763
2022$19,002
2023$23,939
2024$21,150

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 279 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.